Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3
AssigneeSt. Jude Children's Research Hospital
InventorsMireya VELASQUEZ, Stephen GOTTSCHALK, Jaquelyn ZOINE, Nikhil HEBBAR
Life of this patent
Estimating the term…
Abstract
The application provides bispecific chimeric antigen receptors (CARs) targeting glucose-regulated-protein 78 (GRP78) and Cluster of Differentiation 123 (CD123) or GRP78 and B7-homolog 3 (B7H3). The application further provides polynucleotides and recombinant vectors encoding the CARs, as well isolated host cells and methods for preparing isolated host cells that express the CARs. The application further provides pharmaceutical compositions comprising the CAR modified cells and methods for treating a tumor using the CAR modified cells.
Claims42
A polynucleotide encoding a chimeric antigen receptor (CAR) comprising
- a) an extracellular antigen-binding domain comprising one or more glucose-regulated-protein 78 (GRP78)-binding moieties and a CD123-binding moiety;
- b) a transmembrane domain;
- and
- c) a cytoplasmic domain comprising a signaling domain.
3-4. (canceled)
6-7. (canceled)
10-12. (canceled)
15-16. (canceled)
(canceled)
(canceled)
23-25. (canceled)
27-30. (canceled)
32-34. (canceled)
36-38. (canceled)
40-43. (canceled)
46-62. (canceled)
65-69. (canceled)
71-86. (canceled)
89-92. (canceled)
95-98. (canceled)
A polynucleotide encoding a chimeric antigen receptor (CAR) comprising
- a. an extracellular antigen-binding domain comprising one or more glucose-regulated-protein 78 (GRP78)-binding moieties and a B7H3-binding moiety;
- b. a transmembrane domain;
- and
- c. a cytoplasmic domain comprising a signaling domain.
100-203. (canceled)
Dependencies are inferred from the claim text.